Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 77-81

  Jeong, Jaeheon ^a,b,c   Cho, Byoung Chul ^a,b   Sohn, Joo Hyuk ^a,b   Choi, Hye Jin ^a,b   Kim, Se Hyun ^a,b   Lee, Young Joo ^c   Jung, Min Kyu ^a,b   Shin, Sang Joon ^a,b   Park, Moo Suk ^b   Kim, Se Kyu ^b   Chang, Joon ^b   Kim, Joo Hang ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Belotecan; SCLC; Topoisomerase I inhibitor

Indexed keywords

BELOTECAN; CARBOPLATIN; CISPLATIN; IRINOTECAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; TOPOISOMERASE I INHIBITORS;

EID: 77956185923     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.006     Document Type: Article

References (22)

1. Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340(4):265-271.
2. Rosti G., Bevilacqua G., Bidoli P., Portalone L., Santo A., Genestreti G. Small cell lung cancer. Ann Oncol 2006, 17(Suppl. 2):ii5-ii10.
3. Eckardt J.R., von Pawel J., Manikhas G., Papai Z., Tomova A., Tzekova V., et al. Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small cell lung cancer (ED-SCLC): final results of a randomized phase III trial (389). J Clin Oncol 2005, 23(Suppl.):621s. (abstr 7003).
4. Mavroudis D., Papadakis E., Veslemes M., Tsiafaki X., Stavrakakis J., Kouroussis C., et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001, 12(4):463-470.
5. Sundstrøm S., Bremnes R.M., Kaasa S., Aasebø U., Hatlevoll R., Dahle R., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20(24):4665-4672.
6. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346(2):85-91.
7. Hanna N., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24(13):2038-2043.
8. Lara P.N., Natale R., Crowley J., Lenz H.J., Redman M.W., Carleton J.E., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol: Off J Am Soc Clin Oncol 2009, 27(15):2530-2535.
9. Lee J.H., Lee J.M., Lim K.H., Kim J.K., Ahn S.K., Bang Y.J., et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann NY Acad Sci 2000, 922:324-325.
10. Lee J.H., Lee J.M., Kim J.K., Ahn S.K., Lee S.J., Kim M.Y., et al. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998, 21(5):581-590.
11. Lee D., Kim S.W., Suh C., Lee J.S., Lee J., Lee S.J., et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 2007.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
13. Chang M.N., Therneau T.M., Wieand H.S., Cha S.S. Designs for group sequential phase II clinical trials. Biometrics 1987, 43(4):865-874.
14. Spiro S.G., Souhami R.L., Geddes D.M., Ash C.M., Quinn H., Harper P.G., et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989, 59(4):578-583.
15. O'Brien M.E., Ciuleanu T.E., Tsekov H., Shparyk Y., Cucevi B., Juhasz G., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24(34):5441-5447.
16. Tiseo M., Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2007, 2(8):764-772.
17. Beretta G.L., Perego P., Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006, 13(27):3291-3305.
18. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol 1999, 17(2):658-667.
19. Takeda K., Negoro S., Sawa T., Nakagawa K., Kawahara M., Isobe T., et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 2003, 4(4):224-228.
20. Timmer-Bonte J.N., de Boo T.M., Smit H.J., Biesma B., Wilschut F.A., Cheragwandi S.A., et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol: Off J Am Soc Clin Oncol 2005, 23(31):7974-7984.
21. Cullen M., Steven N., Billingham L., Gaunt C., Hastings M., Simmonds P., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353(10):988-998.
22. Tjan-Heijnen V.C., Postmus P.E., Ardizzoni A., Manegold C.H., Burghouts J., van Meerbeeck J., et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2001, 12(10):1359-1368.